PRESS RELEASE published on 05/12/2025 at 07:31, 1 year ago adesso SE increases sales by 11% to EUR 353.4 million in the first quarter of 2025 / EBITDA of EUR 17.8 million at the level of the previous year, which benefited from other operating income adesso SE reports 11% increase in sales to EUR 353.4 million in Q1 2025 with stable EBITDA of EUR 17.8 million, driven by digital transformation demand and market growth EBITDA Digital Transformation Sales Increase Adesso SE Q1 2025
PRESS RELEASE published on 05/12/2025 at 07:30, 1 year ago EQS-WpÜG: Tender Offer / Target company: ProSiebenSat.1 Media SE; Bidder: PPF IM LTD PPF IM LTD announces public acquisition offer for up to 29.99% of ProSiebenSat.1 Media SE shares at EUR 7.00 per share. Offer subject to merger control clearances Shareholders Acquisition Offer Merger Control ProSiebenSat.1 Media SE PPF IM LTD
PRESS RELEASE published on 05/12/2025 at 07:30, 1 year ago Salzgitter AG delivers a pre-tax result close to breakeven Salzgitter AG reports pre-tax result close to breakeven in Q1 2025 despite economic challenges and external sales decline. EBITDA at €78.6 million EBITDA Financial Report Salzgitter AG Pre-tax Result Q1 2025
PRESS RELEASE published on 05/12/2025 at 07:30, 1 year ago q.beyond increases earnings and financial strength in Q1 2025 and confirms outlook q.beyond AG increases earnings by 15% in Q1 2025, reaching EBITDA of € 2.3 million. Free cash flow grows to € 0.8 million, with net liquidity at € 39.9 million. Full-year forecast for 2025 confirmed Q.beyond AG Financial Strength Forecast Earnings Q1 2025
PRESS RELEASE published on 05/12/2025 at 07:30, 1 year ago IONOS with strong growth in the first quarter of 2025 – Outlook 2025 concretized IONOS Group SE reports strong growth in Q1 2025 with 80,000 new customers, 19.7% revenue increase, and 23.8% adjusted EBITDA rise. Outlook for 2025: approx. €520 million adjusted EBITDA Revenue Increase IONOS Group SE EBITDA Rise Q1 2025 2025 Outlook
PRESS RELEASE published on 05/12/2025 at 07:30, 1 year ago L'homologation par la FDA américaine du colorant bleu naturel de Fermentalg ouvre la voie à une nouvelle génération de produits biosourcés pour l'industrie agro-alimentaire Fermentalg annonce l'homologation de son colorant bleu naturel par la FDA américaine, une avancée majeure pour l'industrie alimentaire. La commercialisation d'EverzureTM Galdieria promet des alternatives naturelles et durables FDA Industrie Alimentaire FERMENTALG Colorant Bleu Naturel Alternative Naturelle
PRESS RELEASE published on 05/12/2025 at 07:30, 1 year ago The FDA's approval of Fermentalg's natural blue dye paves the way for a new generation of bio-based products in the food industry. Fermentalg's Everzure™ Galdieria, a natural blue dye approved by the FDA, offers innovative biosourced solution for food industry, replacing petroleum-based colorants FDA Approval Food Industry FERMENTALG Natural Blue Dye Everzure™ Galdieria
PRESS RELEASE published on 05/12/2025 at 07:30, 1 year ago Klea Holding démarre fort le deuxième trimestre 2025 avec un nouveau record en avril pour sa filiale Smart Salem Smart Salem établit un nouveau record mensuel avec 18 497 tests en avril 2025, illustrant la croissance continue de l'entreprise. Klea Holding confirme sa stratégie de développement Croissance Performance Smart Salem Klea Holding Record Mensuel
PRESS RELEASE published on 05/12/2025 at 07:30, 1 year ago Klea Holding mark strong start to Q2 2025 with new monthly record in April for its subsidiary Smart Salem Smart Salem, a subsidiary of Klea Holding, achieves a new monthly record by conducting 18,497 tests in April 2025, displaying a 94% year-on-year growth. Growth strategy in progress Growth Strategy Smart Salem Klea Holding Monthly Record Digitalized Medical Analysis
PRESS RELEASE published on 05/12/2025 at 07:30, 1 year ago Informations privilégiées / Autres communiqués MaaT Pharma annonce des données finales prometteuses pour son essai de Phase 1b évaluant MaaT033 dans la Sclérose Latérale Amyotrophique (SLA). Résultats encourageants et implications thérapeutiques importantes Microbiome Ecosystem Therapies MaaT Pharma Sclérose Latérale Amyotrophique Phase 1b Modulation Du Microbiote
Published on 05/27/2026 at 15:25, 3 hours 52 minutes ago LaFleur Announces Upsize of Bought Deal Equity Offerings for Gross Proceeds of C$10 Million
Published on 05/27/2026 at 15:22, 3 hours 55 minutes ago AmeriTrust Announces First Quarter 2026 Financial Results
Published on 05/27/2026 at 15:15, 4 hours 2 minutes ago Storm Exploration Begins Field Program on VMS Target at Gold Standard
Published on 05/27/2026 at 15:00, 4 hours 17 minutes ago Jaguar Health Compliant with Nasdaq Bid Price Rule
Published on 05/27/2026 at 14:49, 4 hours 28 minutes ago Sekur Private Data Signs Defense Distribution Agreement with Elyon International, Marking Strategic Shift to Defense, Government and Enterprise Communications
Published on 05/27/2026 at 18:30, 47 minutes ago Avolta secures 12-year contract at Norfolk International Airport, introducing hybrid formats
Published on 05/27/2026 at 18:13, 1 hour 3 minutes ago Energiekontor AG: Annual General Meeting approves all agenda items by a large majority
Published on 05/27/2026 at 17:45, 1 hour 32 minutes ago Imerys-05-2026-communique-capital-droits-de-vote-au-30-avril-2026
Published on 05/27/2026 at 17:45, 1 hour 32 minutes ago Déclaration des transactions sur actions propres réalisées du 20 au 26 mai 2026
Published on 05/27/2026 at 17:45, 1 hour 32 minutes ago Descriptif du programme de rachat d'actions - Mai 2026
Published on 05/27/2026 at 17:45, 1 hour 32 minutes ago Imerys-05-2026-information-share-capital-and-voting-rights-as-of-30-April-2026
Published on 05/27/2026 at 17:45, 1 hour 32 minutes ago Description of Share buyback program - May 2026